Magnisense and Indicia Announce Joint Testing Platform

By Labmedica staff writers
Posted on 27 Feb 2007
Magnisense (Rosny-sous-Bois, France), a developer of next generation immunoassays for human and animal diagnostics, food safety, and environmental protection, announced the availability of a platform for customers in the diagnostics industry to test systems based on Magnisense's Miatek technology. The platform has been developed within a partnership with Indicia Biotechnology (Lyon, France), an immune technology specialist.

Miatek employs magnetic beads as markers, replacing the traditional enzymatic or fluorescent methods. Magnisense has already developed a portable reader that can identify and quantify accurately a biologic target using superparamagnetic beads as markers.

By linking up with Indicia, Magnisense opens the way for diagnostics or life science companies who wish to use Miatek for their own applications to develop quickly and economically tests which are specifically adapted to the desired markers and based on their own parameters.

Before or after acquiring a license from Magnisense, any of our customers can now rapidly judge the value of our technology thanks to our jointly-developed tests, said Luc Lenglet, CEO of Magnisense. Indicia brings two indispensable skills to the development of Miatek technology: immunoassays and reagents for the magnetic beads.

As well as extending our range of products and services, this partnership with Magnisense allows us to work on what we see as the future generation of immunoassays based on magnetic technology, said Stéphane Legastelois, chairman of Indicia Biotechnology. Companies interested in Magnisense's technology can now see quickly and easily for themselves the advantages such as the increased sensitivity and the quantification of fast testing.

Indicia Biotechnology offers a large range of technologies and assay formats including the enzyme-linked immunosorbant assay (ELISA), latex, lateral flow test, magnetic-beads immunoassay, multiplexing tests based on xMap technology, and antibody services. The whole organization is working towards quality standards in order to ensure that its development and production processes generate maximum performances and meet customer satisfaction.

Magnisense develops and markets a new generation of immunoassays for human and animal diagnostics, food safety, and environmental protection. These innovative immunoassays are based on magnetic bead markers, which deliver the accuracy of laboratory testing with the ease of use of rapid test methods currently on the market.


Related Links:
Magnisense
Indicia Biotechnology

Latest Industry News